Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Exchange Rate Effect (2017 - 2022)

Historic Exchange Rate Effect for Protagonist Therapeutics (PTGX) over the last 6 years, with Q4 2022 value amounting to $75000.0.

  • Protagonist Therapeutics' Exchange Rate Effect rose 24090.91% to $75000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was -$90000.0, marking a year-over-year increase of 2857.14%. This contributed to the annual value of -$90000.0 for FY2022, which is 2857.14% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Exchange Rate Effect stood at $75000.0 for Q4 2022, which was up 24090.91% from -$175000.0 recorded in Q3 2022.
  • Protagonist Therapeutics' Exchange Rate Effect's 5-year high stood at $123000.0 during Q3 2020, with a 5-year trough of -$175000.0 in Q3 2022.
  • Moreover, its 5-year median value for Exchange Rate Effect was -$14000.0 (2019), whereas its average is -$14666.7.
  • Data for Protagonist Therapeutics' Exchange Rate Effect shows a peak YoY increase of 124444.44% (in 2020) and a maximum YoY decrease of 100000.0% (in 2020) over the last 5 years.
  • Protagonist Therapeutics' Exchange Rate Effect (Quarter) stood at -$87000.0 in 2018, then crashed by 43.68% to -$125000.0 in 2019, then surged by 116.8% to $21000.0 in 2020, then increased by 4.76% to $22000.0 in 2021, then surged by 240.91% to $75000.0 in 2022.
  • Its last three reported values are $75000.0 in Q4 2022, -$175000.0 for Q3 2022, and -$19000.0 during Q2 2022.